TY - JOUR
T1 - Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas
T2 - a systematic review and synthesis of case reports
AU - Rivera-Francia, Victor M.
AU - Failoc-Rojas, Virgilio E.
AU - Villacorta-Carranza, Robert
AU - Leon Garrido-Lecca, Alejandro
AU - Calle-Villavicencio, Ana
AU - Torres-Mera, Alicia
AU - Valladares-Garido, Mario J.
AU - Huerta-Collado, Yesenia
AU - Motta-Guerrero, Rodrigo
AU - Casanova Marquez, Luis
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - Natural killer/T-cell lymphoma (NK/T-cellL) is an aggressive non-Hodgkin’s lymphoma with limited treatment options for patients who experience disease progression or recurrence after second-line treatment. The use of new therapies, such as pembrolizumab, which involves immune checkpoint blockade mechanisms, is proposed. This systematic review followed the MOSE guidelines and searched PUBMED/MEDLINE, EMBASE, and Scopus databases. Fourteen articles were found, reporting on the use of pembrolizumab anti PD-1 in NK/T-cellL patients. The objective response rate was 84.50%, with disease-free survival ranging from two to 48 months. The complete response rate was 61.6%, and the quality of the reported studies was evaluated to be of high and moderate confidence bias levels in case reports and high bias in clinical trials. Pembrolizumab and others anti PD-1 are treatment options for refractory/recurrent NK/T-cellL, regardless of PD-L1 expression, with good short- and long-term results and low adverse events.
AB - Natural killer/T-cell lymphoma (NK/T-cellL) is an aggressive non-Hodgkin’s lymphoma with limited treatment options for patients who experience disease progression or recurrence after second-line treatment. The use of new therapies, such as pembrolizumab, which involves immune checkpoint blockade mechanisms, is proposed. This systematic review followed the MOSE guidelines and searched PUBMED/MEDLINE, EMBASE, and Scopus databases. Fourteen articles were found, reporting on the use of pembrolizumab anti PD-1 in NK/T-cellL patients. The objective response rate was 84.50%, with disease-free survival ranging from two to 48 months. The complete response rate was 61.6%, and the quality of the reported studies was evaluated to be of high and moderate confidence bias levels in case reports and high bias in clinical trials. Pembrolizumab and others anti PD-1 are treatment options for refractory/recurrent NK/T-cellL, regardless of PD-L1 expression, with good short- and long-term results and low adverse events.
KW - Lymphoma
KW - NK-T-cell
KW - immune checkpoint inhibitors (DeCS-BIREME)
KW - programmed cell death 1 receptor
UR - http://www.scopus.com/inward/record.url?scp=85173441845&partnerID=8YFLogxK
U2 - 10.1080/10428194.2023.2264431
DO - 10.1080/10428194.2023.2264431
M3 - Artículo
C2 - 37794819
AN - SCOPUS:85173441845
SN - 1042-8194
VL - 65
SP - 37
EP - 47
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -
